Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 94Leukemia, Myeloid, Chronic-Phase 25Leukemia 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Gastrointestinal Stromal Tumors 15Blast Crisis 9Neoplasms 8Neoplasm Metastasis 6Philadelphia Chromosome 4Myeloproliferative Disorders 4Melanoma 4Leukemia, Myeloid 4Bone Marrow Diseases 4Recurrence 3Leukemia, Myeloid, Acute 3Leukemia, Myeloid, Accelerated Phase 3Hematologic Diseases 3Bronchiolitis Obliterans Syndrome 3Synovitis, Pigmented Villonodular 2Ovarian Neoplasms 2Neoplasm, Residual 2Hematologic Neoplasms 2Colorectal Neoplasms 2Substance Withdrawal Syndrome 1Sarcoma 1Retroperitoneal liposarcoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Piebaldism 1Peritoneal Neoplasms 1Neurofibromatoses 1

Interventions

Carboplatin 159Paclitaxel 153Bevacizumab 85Taxes 48Gemcitabine 48liposomal doxorubicin 47Topotecan 41Cisplatin 35pembrolizumab 33Cyclophosphamide 27olaparib 25Immunoglobulin G 24Disulfides 24Specimen Handling 21Drug Therapy 20Docetaxel 20niraparib 18Magnetic Resonance Spectroscopy 18Doxorubicin 17Biopsy 15mirvetuximab soravtansine 14Hyperthermic Intraperitoneal Chemotherapy 14rucaparib 13Nivolumab 12Cytoreduction Surgical Procedures 11Chemotherapy, Adjuvant 10Albumin-Bound Paclitaxel 10veliparib 9Platinum 9Neoadjuvant Therapy 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × nilotinib × Clear all
NCT05564377 2026-05-27

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
2,900 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡